Home Who We Are In the News Page 2

In the news.

FDA approves first CAR T-cell therapy for CLL/SLL.

The FDA approved Breyanzi last week as the first CAR T-cell therapy to treat refractory for resistant chronic lymphocytic leukemia and small lymphocytic lymphoma.

FDA approves first CAR T-cell therapy for CLL/SLL.

The FDA approved Breyanzi last week as the first CAR T-cell therapy to treat refractory for resistant chronic lymphocytic leukemia and small lymphocytic lymphoma.

Common questions and answers about TIL therapy for cancer.

The FDA approved the first TIL therapy for cancer on Feb. 16 with the approval of Amtagvi to treat advanced melanoma. Here are common questions and answers about this cancer cell therapy.

Common questions and answers about TIL therapy for cancer.

The FDA approved the first TIL therapy for cancer on Feb. 16 with the approval of Amtagvi to treat advanced melanoma. Here are common questions and answers about this cancer cell therapy.

ACGT donor shares desire to make ‘real impact’ in cancer research.

Leigh Haskell Perkins III shares how at a young age she became an ACGT donor and supporter of advancing cell and gene therapy research, which she continues today.

ACGT donor shares desire to make ‘real impact’ in cancer research.

Leigh Haskell Perkins III shares how at a young age she became an ACGT donor and supporter of advancing cell and gene therapy research, which she continues today.